Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
January 08, 2018 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to announce the results of the Special Meeting of Stockholders held on January 5, 2018. ...
Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing
January 03, 2018 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Patrick Murphy as Senior Vice President, Manufacturing. Patrick...
Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
December 11, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase...
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
November 17, 2017 16:05 ET
|
Anthera Pharmaceuticals, Inc.
Delisting notice was expected as part of the compliance extension previously granted by NasdaqContinue “ANTH” listing until formal hearing process is complete with the Nasdaq Hearings Panel HAYWARD,...
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
November 09, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that patient recruitment is now complete for the Phase 3 RESULT clinical study of...
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results
November 06, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
RESULT, Phase 3 clinical study of Sollpura, topline data expected Q1 2018RESULT sanctioned by the European Cystic Fibrosis Society Clinical Trial NetworkBlisibimod granted FDA orphan drug designation...
Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting
November 05, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel...
Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference
November 02, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that data from the SOLUTION, Phase 3 clinical study of Sollpura (liprotamase) and an...
Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting
November 01, 2017 17:00 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present new data from the CHABLIS-SC1 Phase 3 clinical study of blisibimod, a novel treatment that...
Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering
October 24, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has entered into a definitive agreement with certain institutional and...